John Lechleiter
Chief executive: Lilly ELI & Co. (before 2014 to 31 Dec 2016)
4commitments announced
0with a clear outcome
0met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Lilly ELI & Co. filing.
Commitments announced under John Lechleiter
| Lilly ELI & Co.announced 25 Oct 2016 | Submit Taltz regulatory filing to the FDA due after leader left | No record found30 Jun 2017 |
| Lilly ELI & Co.announced 26 Apr 2016 | Begin enrolling participants in the DAYBREAK Phase 3 trial for AZD3293 | No record found30 Sep 2016 |
| Lilly ELI & Co.announced 26 Apr 2016 | Begin two outcome trials investigating Jardiance for chronic heart failure due after leader left | No record found26 Apr 2017 |
| Lilly ELI & Co.announced 28 Jan 2016 | Launch Basaglar in the U.S | No record found15 Dec 2016 |
Is this record wrong, or are you John Lechleiter? Add a statement or ask for a correction.